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Abstract
Developmental competence of in vitro matured (IVM) oocytes needs to be improved and this can potentially be achieved by
adding recombinant bone morphogenetic protein 15 (BMP15) or growth differentiation factor (GDF9) to IVM. The aim of
this study was to determine the effect of a purified pro-mature complex form of recombinant human BMP15 versus the
commercially available bioactive forms of BMP15 and GDF9 (both isolated mature regions) during IVM on bovine embryo
development and metabolic activity. Bovine cumulus oocyte complexes (COCs) were matured in vitro in control medium or
treated with 100 ng/ml pro-mature BMP15, mature BMP15 or mature GDF9 +/2 FSH. Metabolic measures of glucose uptake
and lactate production from COCs and autofluorescence of NAD(P)H, FAD and GSH were measured in oocytes after IVM.
Following in vitro fertilisation and embryo culture, day 8 blastocysts were stained for cell numbers. COCs matured in
medium +/2 FSH containing pro-mature BMP15 displayed significantly improved blastocyst development (57.763.9%,
43.564.2%) compared to controls (43.362.4%, 28.963.7%) and to mature GDF9+FSH (36.163.0%). The mature form of
BMP15 produced intermediate levels of blastocyst development; not significantly different to control or pro-mature BMP15
levels. Pro-mature BMP15 increased intra-oocyte NAD(P)H, and reduced glutathione (GSH) levels were increased by both
forms of BMP15 in the absence of FSH. Exogenous BMP15 in its pro-mature form during IVM provides a functional source of
oocyte-secreted factors to improve bovine blastocyst development. This form of BMP15 may prove useful for improving
cattle and human artificial reproductive technologies.
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Introduction
The oocyte and the somatic cells surrounding the oocyte
(cumulus cells in antral follicles) communicate via a complex bi-
directional signalling axis mediated via paracrine and gap
junctional means [1]. This communication is important for
transporting molecules such as growth factors, cyclic nucleotides,
amino acids and other small regulatory molecules from cumulus
cells into oocytes, and vice versa, in order to sustain cumulus cell
health and oocyte development [1–4]. Oocyte-secreted growth
factors (OSFs) act on cumulus cells to regulate multiple functions,
including; differentiation of the cumulus cell lineage [5], the
proliferation and expansion of cumulus cells [6–9], prevention of
luteinisation [5,10] and apoptosis [11] and regulation of cumulus
cell metabolism [12–14]. Healthy cumulus cells are vitally
important for the development of oocytes through the provision
of substrates and regulatory molecules, required for the oocyte to
undergo appropriate developmental programming in order to
support early embryo development [15].
Growth differentiation factor 9 (GDF9) and bone morphoge-
netic protein 15 (BMP15) are two major and well-known OSFs,
required for follicular development and ovulation [16–19]. The
function and expression of both proteins differs markedly between
species [20]. In polyovular animals, oocyte expression of GDF9 is
notably higher than BMP15, suggesting a minor role for BMP15
in the regulation of their reproduction. Consistent with this notion,
homozygous mutant GDF9 mice are sterile due to a block in
follicular development beyond the primary follicle stage [16],
whereas BMP15 homozygous mutant mice demonstrate only a
mild reduction in fertility [21]. In contrast, in monoovulatory
animals, the ratio of oocyte GDF9 to BMP15 is nearly equal [20],
reflecting the importance of both of these growth factors in follicle
development in these species. Sheep homozyous for certain
naturally occuring mutations in either GDF9 or BMP15 are
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sterile [17,18]. Interestingly, sheep heterozygous for these mutant
forms of GDF9 or BMP15 have an increased ovulation rate and
incidence of mutiple pregnancies due to increased LH sensitivity in
secondary follicles that leads to a rise in the number of antral
follicles [17,18,22]. Furthermore, in humans, rare mutations and
genetic variance of GDF9 and BMP15 are associated with
polycystic ovary syndrome [23], dizygotic twinning [24] and
premature ovarian failure [25–27].
Like other members of the TGFb superfamily, the pro-proteins
(un-processed proteins) of GDF9 and BMP15 are composed of a
pro-region and a mature region [28]. The pro-regions of these
proteins can only be dissociated from the corresponding mature
regions after processing at their protease processing site, after
which they form a pro-mature complex held together by non-
covalent interactions [29]. There still remains considerable
uncertainty exactly which forms of GDF9 and BMP15 are
secreted by the oocyte to act on the surrounding cumulus cells,
and whether the form of these proteins produced by oocytes
matured in vitro is similar to what may occur in vivo. However, a
recent study has shown that in vitro, but not in vivo, matured
mouse COCs are deficient in the mature domain of BMP15 [30].
Moreover, sheep follicular fluid contains GDF9 and BMP15
proteins only in the unprocessed pro-protein form [31], whereas
sheep oocytes secrete the mature domains of GDF9 and BMP15
during IVM [32]. In vitro matured mouse oocytes secrete GDF9
as a mixture of the pro-protein and mature domain [33], whilst in
vitro matured rat oocytes secrete mature domain GDF9 only [32].
Commercially available GDF9 and BMP15 proteins from the one
supplier of these peptides (R&D Systems) contain only the mature
regions of these proteins; however, our novel BMP15 contains
both pro and mature regions, as a processed pro-mature complex.
Consistent with the role of pro-regions of other TGFb superfamily
members, it has now been demonstrated that the pro-regions of
GDF9 interact with cumulus cells [34]. Hence, we hypothesised
that the presence of the pro-region is important to retain the full
function of BMP15 or GDF9 and may affect oocyte developmental
competence.
Our group has previously shown that addition of partially
purified GDF9 or BMP15, which contains a mixture of proteins
including the pro-mature complex form, to in vitro maturation
(IVM) medium improves mouse and cattle blastocyst development
[35–37]. Moreover, addition of a purified BMP15 pro-mature
complex to IVM medium increases bovine embryo development
[14,38]. By contrast, we have recently shown that addition of the
isolated mature homodomains of GDF9 and/or BMP15 (from
R&D Systems) has no effect on mouse IVM [39]. No studies to
date have directly compared the effect of the form of GDF9 or
BMP15 added during IVM on embryo development. In this study,
we examined the effect of the mature (R&D Systems) and pro-
mature (in-house) forms of human BMP15, as well as the mature
form of mouse GDF9 (R&D Systems), on bovine oocyte
developmental competence following IVM. We examined the
metabolic activity of COCs, including glucose uptake and lactate
production, as well as mitochondrial and antioxidant activity that
occurred during the maturation of bovine oocytes.
Materials and Methods
Unless otherwise specified, all chemicals and reagents were
purchased from Sigma (St Louis, MO).
Collection of cells
Bovine ovaries were collected from a local abattoir (T&R
Pastoral, Murray Bridge, South Australia) and transported to the
laboratory in 30–35uC saline. Cumulus-oocyte complexes (COCs)
and mural granulosa cells (GCs) were aspirated from 3–8 mm
antral follicles using an 18-gauge needle and a 10 ml syringe. The
follicular fluid containing COCs was transferred into a 10 ml
Falcon tube at 39uC. The follicular aspirate was allowed to
sediment and the cellular pellet was washed with handling medium
(HEPES-buffered tissue cultured medium-199; TCM-199, MP
Biomedicals, Solon, OH, USA) supplemented with 4 mg/ml fatty-
acid-free bovine serum albumin (FAF-BSA; ICPbio Ltd, Auck-
land, NZ). Intact COCs with compact cumulus cells,.3 cell layers
and with an evenly pigmented oocyte cytoplasm, were selected
under a dissecting microscope and washed twice in handling
medium.
Granulosa cell thymidine assay
To confirm that the forms of recombinant GDF9 and BMP15
used in this study were bioactive on bovine ovarian cells, a
standard granulosa cell tritiated thymidine incorporation bioassay
was performed, as previously described [6,40]. In brief, GCs were
collected from 3–8 mm follicles. The GCs were washed twice in
protein-free culture medium (bicarbonate-buffered TCM-199).
Cells were added to the wells of 96-well plates (Falcon) at a final
concentration of 506104 cells/ml, and cultured at 37uC, 96%
humidity in 5% CO2 in air for 18 hours, followed by a further
6 hour pulse of 15.4 kBq tritiated thymidine ([3H]-thymidine, MP
Biomedicals) under the same conditions. Following culture, GCs
were harvested and incorporated [3H]-thymidine was quantified
using a scintillation counter as an indicator of GC DNA synthesis.
Each treatment was performed in duplicate and the assay was
repeated five times.
Sources of BMP15 and GDF9 and treatment of cumulus-
oocyte complexes
COCs were matured in base IVM medium [bicarbonate-
buffered TCM 199+4 mg/ml FAF BSA +/20.1 IU/ml FSH
(Puregon, Organon, Oss, Netherlands)] in a 4-well Nunc dish
(Nunclon, Denmark) and cultured for 23 hours at 39uC with 5%
CO2 in humidified air. Recombinant mouse mature region GDF9
(Cat No: 739-G9) and human mature region BMP15 (Cat No:
5096-BM) were purchased from R&D Systems (Minnaepolis, MN,
USA).
The recombinant human pro-mature complex of BMP15 was
produced from a stable human embryonic kidney (HEK)-293T
cell line generated in our laboratory. Briefly, an expression cassette
encoding the human BMP15 DNA sequence was synthesized
(Genscript USA, Inc., Piscataway, NJ) incorporating the rat serum
albumin signal sequence at the 59 end followed by a His8 tag and a
Strep II epitope tag at the N-terminus of the BMP15 pro-region.
This expression cassette was transferred to the pEF-IRES
expression vector, as previously described [41] and stably
transfected HEK-293T cell lines producing human BMP15 were
established via puromycin selection. For production of the BMP15
protein, confluent monolayers were transferred to serum-free
media (DMEM/F12 +0.1 mg/ml BSA +125 IU/ml heparin) for a
48 hour collection period. The resultant BMP15 protein was
secreted into the serum-free media with a processing efficiency of
cleavage of the pro and mature regions of over 90%. The BMP15
containing production media was subjected to immobilized Ni2+
based ion-affinity purification targeting the His-tag as described
previously [42]. Samples were tested for the presence of pro-
mature BMP15 protein by silver staining (Fig. 1A). The dose of
processed mature region was quantified using Western blotting
with the mab28 monoclonal antibody [42] and the commercially
Pro-Mature BMP15 Improves Oocyte Quality
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available mature region of hBMP15 (R&D Systems) as a standard
(Fig. 1B).
The effects of graded doses of the purified pro-mature BMP15
were tested at 10, 100 and 200 ng/ml. Four replicate experiments
were performed with 30–40 COCs per dose per replicate. The
concentration of pro-mature BMP15 was chosen based on this
dose-response assessment of embryo development. For all further
experiments the treatment media contained pro-mature BMP15,
mature BMP15 or mature GDF9 at 100 ng/ml+/20.1 IU/ml
FSH. Six replicate experiments were performed with 30–40 COCs
per treatment per replicate.
In vitro fertilization (IVF) and embryo culture
In vitro production of embryos was undertaken using defined,
serum-free media (Bovine Vitro series of media, IVF Vet
Solutions, Adelaide, Australia), as previously described [37].
Frozen semen was donated by SEMEX Australia from a single
bull of proven fertility and was used in all experiments. Briefly,
thawed semen was layered over a discontinuous (45%: 90%)
Percoll gradient (GE Health Care, Australia) in a 12 ml Falcon
tube (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged
for 20–25 minutes at 2716g. The supernatant was removed and
the pellet resuspended in wash medium [VitroWash (IVF Vet
Solutions)+4 mg/ml FAF BSA)] and centrifuged for 5 minutes at
566g. The supernatant was removed and the pellet re-suspended
in IVF medium [VitroFert (IVF Vet Solutions)+4 mg/ml FAF
BSA+10 IU/ml heparin] with a final concentration of 16106
spermatozoa/ml. COCs were inseminated in pre-equilibrated
drops of IVF medium for 23 h at 39uC in 6% CO2 in humidified
air. Post-insemination, cumulus cells were removed by manual
pipetting with a 1000 ml Gilson pipette. Five presumptive zygotes
were cultured in 20 ml drops of pre-equilibrated cleavage medium
[VitroCleave (IVF Vet Solutions)+4 mg/ml BSA+1 mM L-
carnitin] overlaid with mineral oil at 39uC in 5% O2, 6% CO2
and balanced with N2, for 5 days. On day 5, embryos were
transferred into pre-equilibrated blastocyst medium [VitroBlast
(IVF Vet Solutions)+4 mg/ml BSA+1 mM L-carnitin] and
Figure 1. Purification and quantification of pro-mature BMP15. A. Silver stained SDS-polyacrylamide gel of BMP15 samples. The pro-region
appeared as two ,40 KDa bands and the mature region as a ,16 KDa band and as a ,17 KDa band that has been reported to be O-linked
glycosylated [68]. Lane 1: flow through. Lanes 2–3: wash 1–2. Lanes 4–7: eluted fractions 1–4. B. The processed mature region of pro-mature BMP15
was quantified by Western blotting [mab28 monoclonal antibody [42]] using the mature region of hBMP15 (R&D Systems) as a standard. Lanes 1–4:
mature region of BMP15 (R&D Systems); 200, 100, 50 and 10 ng, respectively. Lanes 5–7: decreasing doses of the purified BMP15 pro-mature complex.
doi:10.1371/journal.pone.0103563.g001
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cultured for another 3 days. Blastocysts were assessed on day 7 and
day 8.
Blastocyst differential staining
Differential staining was performed using a modified method
described by [43]. Expanded, hatching and hatched blastocysts
were placed into 1% (v/v) Triton X-100 containing 1 mg/ml
propium iodide for 20–30 seconds. Blastocysts were washed in
absolute ethanol before incubation in 2.5 mg/ml Hoechst 33342
solution for 2 minutes, then mounted in a drop of glycerol in PBS
on microscope slides and covered with a cover slip. Embryos were
examined under a fluorescence microscope (Nikon, TE 2000-E) at
2006 equipped with an ultraviolet filter (excitation, 340–380 nm;
emission, 440–480 nm). The inner cell mass (ICM) appeared blue
and trophectoderm (TE) nuclei stained pink. 22–38 blastocysts
were stained in each treatment group.
Glucose and lactate measurements
Groups of 10 COCs were matured in 100 ml of IVM medium.
After 23 h COC maturation, spent media were analysed for
glucose and lactate levels using a Hitachi 912 chemical analyser (F.
Hoffmann-La Roche Ltd; Basel, Switzerland). This assay is based
on an enzymatic reaction for glucose consumption and enzymatic
colorimetric determination for lactate production. Glucose uptake
and lactate production are expressed as pmol/COC/h. Twelve
replicate experiments were performed with 10 COCs per
treatment, per replicate.
Autofluorescence of NAD(P)H and FAD
NAD(P)H and FAD levels in the oocyte following IVM were
measured by autofluorescence using methodologies previously
described and validated [44]. Briefly, ten COCs were matured in
100 ml of IVM medium. At 23 h maturation, COCs were denuded
and oocytes were transferred into 10 ml drops of handling medium
overlaid with mineral oil in glass-bottomed confocal dishes (Cell
E&G; Houston, TX, USA). The autofluorescent intensity of FAD
was observed using a blue laser (excitation, 473 nm; emission,
490–520 nm), and NAD(P)H using a violet laser (excitation;
405 nm, emission: 420–520 nm) with a confocal microscope
(Olympus; Fluoview FV10i). These measurements were calibrated
as previously described [14,45]. The fluorescence from the oocytes
was normalized using a fluorescence standard (Inspeck; Molecular
Probes). Laser power, gain and pin-hole settings were kept
consistent. Four replicate experiments were performed with 10
oocytes per treatment group for each experiment (n = 4).
Reduced glutathione (GSH)
At 23 h maturation, COCs were denuded and washed in
handling medium. Denuded oocytes were incubated for 30 min-
utes in 12.5 mM monochlorobimane (MCB, Catt No: 69899) and
transferred into 10 ml drops of handling medium overlaid with
mineral oil in glass-bottomed confocal dishes (Cell E&G; Houston,
TX, USA). The fluorescent intensity was observed using a DAPI
filter (excitation, 358 nm; emission, 461 nm) with a confocal
microscope (Olympus; Fluoview FV10i). Ten COCs were
measured per treatment group per replicate and each experiment
was replicated 3 times.
Statistical analysis
All proportional data for embryo development were arcsine
transformed prior to analysis using multivariate analysis of
variance (ANOVA). Log transformation was performed if the
data were not normally distributed, and analysed using one-way
ANOVA for blastoycst cell numbers, glucose production and
lactate consumption. Autofluorescence of NADP(H), FAD and
GSH were analysed by two-way ANOVA and as there was no
main effect of FSH (P.0.05), subsequently the form of GDF9/
BMP15 was tested within +/2 FSH treatment by one-way-
ANOVA followed by a least-significant difference (LSD) post hoc
test. All analysis was performed with SPSS version 13 (SPSS Inc,
Chicago, IL, USA). Differences were considered significant at P,
0.05. Data are expressed as mean 6 SEM.
Results
Bioactivity of different BMP15 and GDF9 forms
All forms of the three recombinant proteins (pro-mature
BMP15, mature BMP15 and mature GDF9) were bioactive on
bovine GC, as evidenced by significant stimulation of [3H]-
thymidine incorporation compared to the control (Fig. 2). The
mature region of GDF9 protein tended to cause the highest level of
GC [3H]-thymidine incorporation and pro-mature BMP15 the
least.
Dose-response of pro-mature BMP15 on oocyte
developmental competence
Supplementation of IVM media with pro-mature BMP15 had
no effect on subsequent embryo cleavages rates; however,
significantly increased blastocyst development on day 8 at each
dose examined, compared to control and buffer groups (P,0.05;
Table 1). There was no observable dose-response to BMP15
ranging from the lowest dose (10 ng/ml) to the highest dose
(200 ng/ml); however, 200 ng/ml produced a high blastocyst rate
of 60%; a 1.5-fold higher embryo yield than under control IVM
conditions. No adverse effect of elution buffer (PBS/500 mM
imidazole buffer) during IVM on either cleavage or blastocyst
development was observed (Table 1).
Comparison of pro-mature BMP15, mature BMP15 and
mature GDF9 during IVM on subsequent embryo
development
In the presence of FSH, addition of pro-mature BMP15 to IVM
medium significantly increased blastocyst development on day 7
compared to control (Table 2). Irrespective of treatment, there
were no significant differences in cleavage rates, day 8 blastocyst
rates, inner cell mass, trophectoderm or total cell numbers
(Tables 2 and 3). There was a trend towards an improvement in
blastocyst development on day 8 from pro-mature BMP15
compared to control, but this was not significant (p = 0.07). The
mature form of BMP15 produced intermediate levels of blastocyst
development which were not significantly different to pro-mature
BMP15 or controls. The mature region of GDF9 did not improve
any embryo parameter and blastocyst development on day 7 was
significantly lower than both forms of BMP15 (Table 2).
As expected, in the absence of FSH, all embryo development
and embryo quality measures were generally lower than in the
presence of FSH (Tables 2 and 3). In the absence of FSH,
blastocyst development with pro-mature BMP15 was also signif-
icantly higher than the control on day 7 (P,0.05). The trend for
improved blastocyst development with mature BMP15 in the
presence of FSH was not evident in the absence of FSH. Mature
GDF9 without FSH did not improve embryo development or
quality.
Pro-Mature BMP15 Improves Oocyte Quality
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Effect of pro-mature BMP15, mature BMP15 and mature
GDF9 on COC glucose consumption and lactate
production
None of the BMP15 or GDF9 proteins tested altered COC
glucose consumption or lactate production, regardless of FSH
treatment (P.0.05). As expected, there was an increase in COC
glucose uptake and lactate production (almost 2-fold) in response
to FSH, across all BMP15/GDF9 treatment groups and controls
(Fig. 3).
Effect of pro-mature BMP15, mature BMP15 and mature
GDF9 on oocyte FAD and NAD(P)H autofluorescence
Across all treatments, FSH had no effect on intra-oocyte
NAD(P)H, FAD, or the REDOX ratio, as assessed by confocal
microscopy and analysed by 2-way ANOVA (main effect FSH;
P.0.05). In the absence of FSH, there was significantly higher
autofluorescence of NAD(P)H in the oocytes treated with pro-
mature BMP15 compared to controls (P,0.05, Fig. 4A, Fig. 5A).
However, in the presence of FSH, the NAD(P)H level in controls
increased to the same level as pro-mature BMP15. There was a
significantly lower level of NAD(P)H autofluorescence in oocytes
matured in the presence of GDF9 compared to control and pro-
mature BMP15 groups in the presence of FSH (P,0.05, Fig. 4A,
Fig. 5C). No increase in autofluorescence of FAD (Fig. 4B, Fig. 5B,
5D) or change in REDOX ratio (Fig. 4C) in any treatment groups
was observed compared to controls.
Effect of pro-mature BMP15, mature BMP15 and mature
GDF9 on oocyte GSH
Since a significant increase in NAD(P)H levels in oocytes treated
with pro-mature BMP15 (-FSH) was detected, we then examined
if this was associated with an increase in oocyte GSH, on the basis
that if NADPH increased, then the capacity to regenerate reduced
GSH was a likely consequence. In the absence of FSH, both forms
of BMP15 significantly increased oocyte GSH levels compared to
the controls (Fig. 4D, Fig. 5E). Mature GDF9 produced an
intermediate level of GSH. However, in the presence of FSH, the
GSH level of controls was comparable with all other treatments
(Fig. 4D, Fig. 5F). There was no overall effect of FSH on oocyte
GSH levels (main effect FSH; P.0.05).
Discussion
In this present study, we compared the effects of different forms
of BMP15 (pro-mature and mature) and the mature form of GDF9
Figure 2. Bioactivity of different BMP15 and GDF9 forms. Granulosa cell tritiated thymidine incorporation following exposure to mature
GDF9, mature BMP15 or pro-mature BMP15 at 100 ng/ml. Bars represent mean 6 SEM and different lowercase letters indicate a statistically
significant difference (P,0.05). Data were derived from 5 independent replicates.
doi:10.1371/journal.pone.0103563.g002
Table 1. Effect of graded doses of pro-mature BMP15 during IVM on oocyte developmental competence.
Treatments No. of oocytes Cleavage (%) Blastocyst day 8 per cleaved (%)
Control 151 76.563.3 39.962.3a
Buffer (Imidazole) 500 mM 159 82.266.3 40.964.6a
BMP15 10 ng/ml 151 87.465.1 54.063.3b
BMP15 100 ng/ml 150 83.664.9 55.566.0b
BMP15 200 ng/ml 156 85.861.3 59.764.4b
Values with different superscripts within a column are statistically different (P,0.05). Data are presented as mean 6 SEM of 4 experiment replicates.
doi:10.1371/journal.pone.0103563.t001
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during IVM on bovine embryo development. The pro-mature
form of BMP15 was the only form of OSF that significantly
increased subsequent embryo development relative to the control.
Mature domain GDF9 was ineffective and mature domain BMP15
lead to a moderate, albeit non-significant, improvement in embryo
yield. We have also produced pro-mature human GDF9. It is
known that this form of human GDF9 is naturally latent [46,47]
and consistent with this, we have recently shown that this protein
has no effect on bovine COCs [38]. Moreover, the utilization of
this protein is problematic in culture, as we have found that it has a
very high binding affinity for plastic culture-ware (Mottershead
DG, unpublished data) and we have not yet determined a suitable
culture environment.
Oocyte-secreted growth factors have been studied extensively
either in their native form (i.e. as secreted by oocytes) or as
recombinant growth factors [1]. It is now a well-known concept
that co-culture of denuded oocytes (as a source of native
exogenous OSFs) with COCs improves developmental compe-
tence of mouse [39], pig [48], cattle [35,37,38,49] and goat [50]
IVM oocytes. However, a full characterisation of the forms and
indeed the complete identities of native OSFs has not been
undertaken. Previous results showed that addition of either non-
purified BMP15 or GDF9 (containing pro-mature complexes)
improved cattle blastocyst development, and pro-mature mouse
GDF9 improved mouse fetal yield [35–37]. However, so far, there
is no published report of any significant improvements after
addition of the only commercially available mammalian cell
expressed mature regions of GDF9 or BMP15. Our previous
findings indicated that addition of the mature regions of GDF9 or
BMP15 (R&D Systems) did not improve the developmental
competence of mouse IVM oocytes [39].
Although the form of GDF9 and BMP15 which are produced
by the oocyte and released into the somatic cell compartment of
the follicle remains elusive, it is known that both the pro-region
and mature region play important roles in the function of these
proteins. The mature domain of TGF-b superfamily proteins is the
bioactive receptor binding region, and while the mature domain is
complexed with the pro-region after processing to form the pro-
mature complex, this form can either be latent or active depending
on the particular superfamily member [51–53]. In the case of
human GDF9, the association of the pro-region with its mature
region confers latency [46,47]. Further, the pro-region has
important functions in protein folding, formation of the disulfide
bonds and regulation of bioactivity [51,54]. Indeed the pro-mature
complex of BMP15 was highly effective at enhancing oocyte
quality during IVM [14,38]. It seems plausible that the pro-
Table 2. Effect of supplementing COC during IVM with different forms of BMP15 (mature BMP15 and pro-mature BMP15), mature
GDF9 at 100 ng/ml dose, with and without FSH on oocyte developmental competence.
Treatments FSH No. of oocytes Cleavage (%)
Blastocyst day 7 per cleaved
(%)
Blastocyst day 8 per cleaved
(%)
Control 2 191 76.464.8 28.963.7a 39.363.2
GDF9 mature 2 189 85.563.1 33.169.5a,b 38.464.1
BMP15 mature 2 195 84.967.3 32.364.5a,b 38.563.7
BMP15 pro-mature 2 188 81.664.3 43.564.2b 48.763.8
Control + 214 94.261.4 43.362.4x,y 52.863.9
GDF9 mature + 195 88.863.1 36.163.0y 52.064.1
BMP15 mature + 207 92.161.8 50.162.6x,z 60.063.8
BMP15 pro-mature + 210 89.161.6 57.763.9z 61.76.3.5*
Values with different superscript within a column are statistically different (P,0.05);
a,bminus FSH,
x–zplus FSH.
*p = 0.07 relative to control.
Data are presented as means 6 SEM of 6 replicate experiments.
doi:10.1371/journal.pone.0103563.t002
Table 3. Effect of supplementing COC during IVM with different forms of BMP15 (mature BMP15 and pro-mature BMP15), mature
GDF9 at 100 ng/ml dose, with and without FSH on blastocyst quality.
Treatments FSH Inner cell mass Trophectoderm Total cell number (TCN) ICM/TCN
Control 2 24.561.9 77.365.8 101.866.3 0.2660.02
GDF9 mature 2 27.462.0 73.864.6 101.365.2 0.2860.02
BMP15 mature 2 26.561.8 72.166.7 98.667.9 0.2860.02
BMP15 pro-mature 2 29.161.8 78.666.3 107.767.1 0.2960.02
Control + 30.561.6 59.763.5 90.264.7 0.3460.01
GDF9 mature + 28.761.9 69.765.0 98.466.0 0.3060.01
BMP15 mature + 31.863.0 68.464.4 100.266.2 0.3160.02
BMP15 pro-mature + 34.661.8 63.462.6 97.963.6 0.3560.01
Data represents the mean 6 SEM of 6 replicates. Mean blastocyst cell numbers following differential staining of 22–38 blastocysts.
doi:10.1371/journal.pone.0103563.t003
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domain of BMP15 may interact with the extracellular matrix of
cumulus cells during maturation and facilitate presentation of the
mature domain to cumulus cell receptors. In support of this
concept, it has been shown that the GDF9 pro-mature complex
binds strongly to heparin sepharose, suggesting that heparan
sulfate proteoglycans on cumulus cells may act as co-receptors
mediating oocyte secreted factor signalling [34]. Collectively, these
results indicate that the pro-domains of GDF9 and BMP15 exhibit
important interactions with ovarian somatic cells, and may explain
why the isolated mature regions of GDF9 and BMP15 appear to
have little effect on oocyte developmental competence.
In vitro matured COCs have aberrant expression of genes and
proteins compared to COCs matured in vivo [55–57]. Notably,
mouse COCs express processed BMP15 protein during in vivo
oocyte maturation, but not during IVM [30]. From our data, it is
clear that BMP15 improved bovine embryo development com-
pared to GDF9. However, GDF9 may have the capability to
improve oocyte quality during IVM if it were in a different form;
e.g. as a pro-mature complex or if bovine GDF9 were used instead
of mouse GDF9. Different species origins of recombinant OSFs
have different effects on granulosa cell sterol biosynthesis and
bioactivity [58,59]. Interestingly, mouse GDF9 in its mature form
is significantly more bioactive on bovine granulosa cells compared
to BMP15 (both forms; current study). Hence, the lack of effect of
mouse GDF9 on oocyte competence was not due to lack of
bioactivity of this preparation on bovine cells.
Figure 3. COC glucose consumption and lactate production. Spent IVM medium were analysed for glucose and lactate levels post 23 h
maturation of COCs after treatment with different forms of BMP15 (mature BMP15 and pro-mature BMP15) or mature GDF9 at 100 ng/ml, in the
absence or presence of FSH. A. Glucose uptake. B. Lactate production. Bars represent the mean 6 SEM. Data were derived from 12 independent
replicates for each treatment.
doi:10.1371/journal.pone.0103563.g003
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The improvement of embryo development after addition of pro-
mature BMP15 was accompanied by an increase in oocyte
autofluorescence of NAD(P)H. However, there was no increase in
oocyte FAD or change in REDOX status. These results differ
slightly from our previous published data which showed that the
addition of pro-mature BMP15 increased not only NAD(P)H but
also increased FAD levels [14]. Unfortunately, we cannot
distinguish between autofluorescence from NADPH derived from
the pentose phosphate pathway (PPP) or isocitrate dehydrogenase
activity, and autofluorescence from NADH, which is a product of
several metabolic pathways including glycolysis, and the tricar-
boxylic acid (TCA cycle). If the increasing level of NAD(P)H in the
oocyte after treatment with pro-mature BMP15 is in part due to
increased NADPH, then this may also relate to the higher levels of
GSH in oocytes, as NADPH is required for reduction of oxidised
glutathione via the enzyme glutathione reductase. Glutathione is
an antioxidant molecule in the cell and acts as a defence
mechanism in oxidative stress [60,61]. Reactive oxygen species
(ROS), such as superoxide anion, react with the thiol of GSH and
oxidise glutathione (GSSG) [60]. As a reducing agent, NADPH
aids in the conversion of GSSG into GSH. Raising the level of
GSH during IVM is well documented to improve oocyte quality
during bovine oocyte maturation [62,63]. Interestingly, even
though there was no increase in NAD(P)H levels in COCs
matured in the presence of mature BMP15, the level of GSH was
significantly increased compared to control. This is perhaps due to
lower levels of ROS production in this group, something that
could be confirmed in future experiments.
The aim of testing the medium in the absence of FSH was to
observe the function of exogenous growth factors on IVM oocytes
without any influence of metabolic activators. Cumulus cell
function during IVM is profoundly altered by FSH treatment,
Figure 4. Quantification of intra-oocyte NAD(P)H, FAD, REDOX ratio and GSH. Effect of treatment of intact COCs with different forms of
BMP15 (mature BMP15 and pro-mature BMP15) or mature GDF9 at 100 ng/ml, +/2 FSH on intra-oocytemetabolic activity. A. Autofluorescence of
NAD(P)H. B. Autofluorescence of FAD. C. REDOX ratio (FAD/NAD(P)H). D. GSH levels. Bars represent the mean 6 SEM. Data were derived from 4
independent replicates for autofluorescence on intra-oocyte NAD(P)H, FAD, and REDOX ratio and 3 independent replicates for GSH levels. Columns
with different superscripts are significantly different (P,0.05); a,bminus FSH, x–yplus FSH.
doi:10.1371/journal.pone.0103563.g004
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including cumulus cell energy metabolism [64]. The present study
shows that in the absence or presence of FSH, the addition of pro-
mature BMP15 to IVM increases significantly embryo develop-
ment on day 7 and yielded more blastocysts on day 8 compared to
any other group. As expected, FSH also improved IVM outcomes.
However, in the presence of FSH, the influence of recombinant
OSFs on NAD(P)H and GSH levels were diminished. These
results are similar with the previous reports that showed FSH can
mask the influence of OSFs on cumulus cell metabolism [14,65].
It is well established that during IVM, COCs utilise glucose as
the principal energy source and glucose consumption increases
linearly with oocyte maturation [66]. In this present study, glucose
uptake and lactate production were measured in the presence or
absence of FSH. It has been shown that in the absence of
alteration of metabolism by FSH, the influence of OSFs on
glycolytic activity leads to the activation of oxidative phosphory-
lation in mitochondria to produce ATP, rather than lactate
production [13,14]. Our collaborators have shown that addition of
mature BMP15 increases glucose uptake but has no effect on
lactate production by Nellore (Bos indicus) bovine COCs, under
slightly different culture conditions [67]. We did not observe any
increases in glucose uptake in any OSF treatment group, including
with mature BMP15, in the presence or absence of FSH. This
result is supported by our previous study [14].
In conclusion, we found that the form of the oocyte-secreted
growth factors GDF9 and BMP15 is an important determinant of
their function during oocyte IVM, and that it affects subsequent
embryo development. Only the pro-mature form of BMP15 added
in IVM medium significantly improved oocyte developmental
competence, and importantly from a practical perspective, there
was no evidence that the only commercially available mammalian
forms of GDF9 and BMP15 could increase cattle embryo
production. Improvement of bovine IVM oocyte competence,
may be, in part, due to an increase in oocyte NAD(P)H and GSH.
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